GlassScriptPhysician profile
Robert B Penne
NPI 1215936380
$2,183.45
in general payments reported to CMS, 2019-2025
14 companies · $323 in 2025
The $323 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,108 · 2020: $166 · 2021: $28.07 · 2022: $328 · 2023: $95.99 · 2024: $134 · 2025: $323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $553.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $1,373.02 | 2019-2023 | Tepezza |
| Amgen INC. | $266.21 | 2024-2025 | Tepezza |
| Genentech USA, INC. | $117.35 | 2022 | |
| Merz Pharmaceuticals, LLC | $77.12 | 2023-2025 | Xeomin |
| Harrow Eye, LLC | $55.06 | 2025 | Vevye, Iheezo |
| Ani Pharmaceuticals, INC. | $49.55 | 2024 | Purified Cortrophin Gel |
| Oyster Point Pharma, INC. | $42.89 | 2022 | |
| Sun Pharmaceutical Industries INC. | $40.43 | 2025 | |
| Shire North American Group INC | $32.63 | 2019 | |
| Aroa Biosurgery Incorporated | $32.04 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $28.43 | 2021-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $26.22 | 2019-2021 | |
| Biotissue Holdings INC. | $23.10 | 2023 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Penne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.